Iacopo Olivotto

38.8k total citations · 12 hit papers
396 papers, 17.7k citations indexed

About

Iacopo Olivotto is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, Iacopo Olivotto has authored 396 papers receiving a total of 17.7k indexed citations (citations by other indexed papers that have themselves been cited), including 336 papers in Cardiology and Cardiovascular Medicine, 68 papers in Epidemiology and 64 papers in Molecular Biology. Recurrent topics in Iacopo Olivotto's work include Cardiomyopathy and Myosin Studies (279 papers), Cardiovascular Function and Risk Factors (154 papers) and Cardiovascular Effects of Exercise (121 papers). Iacopo Olivotto is often cited by papers focused on Cardiomyopathy and Myosin Studies (279 papers), Cardiovascular Function and Risk Factors (154 papers) and Cardiovascular Effects of Exercise (121 papers). Iacopo Olivotto collaborates with scholars based in Italy, United States and United Kingdom. Iacopo Olivotto's co-authors include Franco Cecchi, Barry J. Maron, Martin S. Maron, Susan A. Casey, Paolo G. Camici, John R. Lesser, James E. Udelson, Stefano Nistri, Francesca Girolami and Alberto Dolara and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Iacopo Olivotto

379 papers receiving 17.2k citations

Hit Papers

Effect of Left Ventricular Outflow Tract Obstruction on C... 2000 2026 2008 2017 2003 2006 2000 2001 2000 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy
    2003 995 citations Martin S. Maron, Iacopo Olivotto et al. profile →
  2. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
    2006 692 citations Martin S. Maron, Iacopo Olivotto et al. Circulation profile →
  3. Short-Term Clinical Outcome of Patients With Acute Pulmonary Embolism, Normal Blood Pressure, and Echocardiographic Right Ventricular Dysfunction
    2000 585 citations Iacopo Olivotto et al. Circulation profile →
  4. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy
    2001 563 citations Iacopo Olivotto, Franco Cecchi et al. Circulation profile →
  5. Epidemiology of Hypertrophic Cardiomyopathy–Related Death
    2000 559 citations Barry J. Maron, Iacopo Olivotto et al. Circulation profile →
  6. Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy
    2003 551 citations Franco Cecchi, Iacopo Olivotto et al. profile →
  7. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy
    2005 536 citations Steve R. Ommen, Barry J. Maron et al. Journal of the American College of Cardiology profile →
  8. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
    2018 456 citations Carolyn Y. Ho, Sharlene M. Day et al. Circulation profile →
  9. Hypertrophic Cardiomyopathy
    2014 451 citations Barry J. Maron, Steve R. Ommen et al. Journal of the American College of Cardiology profile →
  10. Cardiac Involvement in Fabry Disease
    2021 177 citations Maurizio Pieroni, James Moon et al. Journal of the American College of Cardiology profile →
  11. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
    2021 127 citations Perry Elliott, Carolyn Y. Ho et al. profile →
  12. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
    2024 34 citations Artur Oręziak, Lubna Choudhury et al. JACC Heart Failure profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iacopo Olivotto Italy 64 15.7k 2.9k 2.6k 1.8k 1.4k 396 17.7k
Steve R. Ommen United States 70 20.3k 1.3× 3.6k 1.3× 2.5k 0.9× 3.0k 1.6× 2.7k 1.9× 319 21.8k
Geneviève Dérumeaux France 53 9.6k 0.6× 3.3k 1.1× 1.1k 0.4× 2.1k 1.2× 2.9k 2.0× 219 13.4k
Petros Nihoyannopoulos United Kingdom 56 15.2k 1.0× 3.8k 1.3× 1.4k 0.5× 3.8k 2.1× 3.6k 2.5× 296 19.0k
Gianfranco Sinagra Italy 61 11.7k 0.7× 1.3k 0.4× 4.8k 1.8× 3.0k 1.7× 1.2k 0.8× 679 17.3k
Gad Keren Israel 47 5.7k 0.4× 1.6k 0.6× 1.4k 0.5× 2.1k 1.1× 1.5k 1.0× 372 10.6k
Giuseppe Limongelli Italy 47 8.8k 0.6× 2.1k 0.7× 2.2k 0.8× 1.4k 0.8× 1.1k 0.8× 337 11.5k
David García‐Dorado Spain 47 3.8k 0.2× 1.0k 0.4× 1.8k 0.7× 1.1k 0.6× 809 0.6× 260 6.6k
Harry Rakowski Canada 60 13.1k 0.8× 3.7k 1.3× 1.1k 0.4× 3.1k 1.7× 1.7k 1.2× 209 14.3k
Christian Hengstenberg Austria 46 4.8k 0.3× 1.6k 0.6× 1.3k 0.5× 1.9k 1.0× 897 0.6× 378 7.2k
Marc R. Mayberg United States 56 1.9k 0.1× 4.6k 1.6× 1.5k 0.6× 1.5k 0.8× 604 0.4× 181 12.8k

Countries citing papers authored by Iacopo Olivotto

Since Specialization
Citations

This map shows the geographic impact of Iacopo Olivotto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iacopo Olivotto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iacopo Olivotto more than expected).

Fields of papers citing papers by Iacopo Olivotto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iacopo Olivotto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iacopo Olivotto. The network helps show where Iacopo Olivotto may publish in the future.

Co-authorship network of co-authors of Iacopo Olivotto

This figure shows the co-authorship network connecting the top 25 collaborators of Iacopo Olivotto. A scholar is included among the top collaborators of Iacopo Olivotto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iacopo Olivotto. Iacopo Olivotto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barriales‐Villa, Roberto, Pablo García‐Pavía, Iacopo Olivotto, et al.. (2025). Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 14(6). e038758–e038758. 5 indexed citations
2.
Olivotto, Iacopo, Giancarlo Todiere, Andrea Barison, et al.. (2024). Endpoint Selection in Randomized Clinical Trials for Hypertrophic Cardiomyopathy. JACC Heart Failure. 13(2). 200–212.
3.
García‐Pavía, Pablo, Artur Oręziak, Ahmad Masri, et al.. (2024). Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. European Heart Journal. 45(47). 5071–5083. 38 indexed citations
4.
Tini, Giacomo, Maddalena Graziosi, Beatrice Musumeci, et al.. (2023). Diagnostic delay in arrhythmogenic cardiomyopathy. European Journal of Preventive Cardiology. 30(13). 1315–1322. 2 indexed citations
5.
Ilić, Aleksandra, Lars S. Maier, Nduka C. Okwose, et al.. (2022). Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy—An Analysis from the SILICOFCM Database. Medicina. 58(2). 314–314. 16 indexed citations
6.
Argirò, Alessia, Samuele Baldasseroni, Carlo Fumagalli, et al.. (2022). Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis. Internal and Emergency Medicine. 18(2). 585–593. 5 indexed citations
7.
Žunkovič, Bojan, Marko Robnik‐Šikonja, Matjaž Kukar, et al.. (2022). Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning. JMIR Medical Informatics. 10(2). e30483–e30483. 14 indexed citations
8.
Pieroni, Maurizio, James Moon, Eloisa Arbustini, et al.. (2021). Cardiac Involvement in Fabry Disease. Journal of the American College of Cardiology. 77(7). 922–936. 177 indexed citations breakdown →
9.
Marston, Nicholas, Larry Han, Iacopo Olivotto, et al.. (2021). Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal. 42(20). 1988–1996. 67 indexed citations
10.
Castagno, Davide, Paolo Di Donna, Iacopo Olivotto, et al.. (2021). Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long‐term results and clinical outcomes. Journal of Cardiovascular Electrophysiology. 32(3). 657–666. 13 indexed citations
11.
Hegde, Sheila M., Steven J. Lester, Scott D. Solomon, et al.. (2021). Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 78(25). 2518–2532. 102 indexed citations
12.
Pezoulas, Vasileios C., et al.. (2020). Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study. PubMed. 2020. 5343–5346. 7 indexed citations
13.
Coppini, Raffaele, Luca Mazzoni, Cecilia Ferrantini, et al.. (2017). Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circulation Heart Failure. 10(3). 80 indexed citations
14.
Girolami, Francesca, Giulia Frisso, Matteo Benelli, et al.. (2017). Contemporary genetic testing in inherited cardiac disease. Journal of Cardiovascular Medicine. 19(1). 1–11. 40 indexed citations
15.
Homburger, Julian R., Eric M. Green, Colleen Caleshu, et al.. (2016). Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences. 113(24). 6701–6706. 80 indexed citations
16.
Ammirati, Enrico, Rachele Contri, Raffaele Coppini, et al.. (2016). Pharmacological Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives. European Journal of Heart Failure. 18(9). 1106–1118. 107 indexed citations
17.
Tomberli, Benedetta, Gabriele Castelli, Roberto Spoladore, et al.. (2013). Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 112(8). 1190–1196. 27 indexed citations
18.
Spoladore, Roberto, et al.. (2012). Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. European Heart Journal. 33(14). 1724–1733. 127 indexed citations
19.
Maron, Martin S., Iacopo Olivotto, Caitlin Harrigan, et al.. (2011). Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. Circulation. 124(1). 40–47. 285 indexed citations
20.
Johnson, Jonathan N., Camilla Grifoni, J. Martijn Bos, et al.. (2011). Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. European Heart Journal. 32(9). 1114–1120. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steve R. Ommen Breakdown of academic impact, for papers by Geneviève Dérumeaux Breakdown of academic impact, for papers by Petros Nihoyannopoulos Breakdown of academic impact, for papers by Gianfranco Sinagra Breakdown of academic impact, for papers by Gad Keren Breakdown of academic impact, for papers by Giuseppe Limongelli Breakdown of academic impact, for papers by David García‐Dorado Breakdown of academic impact, for papers by Harry Rakowski Breakdown of academic impact, for papers by Christian Hengstenberg Breakdown of academic impact, for papers by Marc R. Mayberg
Rankless by CCL
2026